Guardant Health’s Liquid Biopsy Test Reveal Gets Expanded Clearance

Guardant Health’s Reveal liquid biopsy test received an expanded clearance from the FDA to include patients with breast and lung cancers.

The test works by detecting circulating tumor DNA in the blood after surgery to identify patients with minimal residual disease who have a higher risk for recurrence and may benefit from additional therapy.

This blood-based test offers an alternative to tissue biopsies which can present a challenge when it comes to obtaining samples, the company said.

The test can be used as early as three weeks after surgery.